Literature DB >> 25422398

Simultaneous consideration of multiple candidate protein biomarkers for long-term risk for cardiovascular events.

Sharif A Halim1, Megan L Neely1, Karen S Pieper1, Svati H Shah1, William E Kraus1, Elizabeth R Hauser1, Robert M Califf1, Christopher B Granger1, L Kristin Newby2.   

Abstract

BACKGROUND: Although individual protein biomarkers are associated with cardiovascular risk, rarely have multiple proteins been considered simultaneously to identify which set of proteins best predicts risk. METHODS AND
RESULTS: In a nested case-control study of 273 death/myocardial infarction (MI) cases and 273 age- (within 10 years), sex-, and race-matched and event-free controls from among 2023 consecutive patients (median follow-up 2.5 years) with suspected coronary disease, plasma levels of 53 previously reported biomarkers of cardiovascular risk were determined in a core laboratory. Three penalized logistic regression models were fit using the elastic net to identify panels of proteins independently associated with death/MI: proteins alone (Model 1); proteins in a model constrained to retain clinical variables (Model 2); and proteins and clinical variables available for selection (Model 3). Model 1 identified 6 biomarkers strongly associated with death/MI: intercellular adhesion molecule-1, matrix metalloproteinase-3, N-terminal pro-B-type natriuretic peptide, interleukin-6, soluble CD40 ligand, and insulin-like growth factor binding protein-2. In Model 2, only soluble CD40 ligand remained strongly associated with death/MI when all clinical risk predictors were retained. Model 3 identified a set of 6 biomarkers (intercellular adhesion molecule-1, matrix metalloproteinase-3, N-terminal pro-B-type natriuretic peptide, interleukin-6, soluble CD40 ligand, and insulin-like growth factor binding protein-2) and 5 clinical variables (age, red-cell distribution width, diabetes mellitus, hemoglobin, and New York Heart Association class) strongly associated with death/MI.
CONCLUSIONS: Simultaneously assessing the association between multiple putative protein biomarkers of cardiovascular risk and clinical outcomes is useful in identifying relevant biomarker panels for further assessment.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  mortality; myocardial infarction; prognosis; protein

Mesh:

Substances:

Year:  2014        PMID: 25422398      PMCID: PMC4334748          DOI: 10.1161/CIRCGENETICS.113.000490

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  11 in total

1.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

Authors:  M A Albert; E Danielson; N Rifai; P M Ridker
Journal:  JAMA       Date:  2001-07-04       Impact factor: 56.272

2.  Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Study.

Authors:  Svati H Shah; Christopher B Granger; Elizabeth R Hauser; William E Kraus; Jie-Lena Sun; Karen Pieper; Charlotte L Nelson; Elizabeth R Delong; Robert M Califf; L Kristin Newby
Journal:  Am Heart J       Date:  2010-09       Impact factor: 4.749

3.  Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults.

Authors:  Christopher R deFilippi; James A de Lemos; Robert H Christenson; John S Gottdiener; Willem J Kop; Min Zhan; Stephen L Seliger
Journal:  JAMA       Date:  2010-11-15       Impact factor: 56.272

4.  Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers.

Authors:  Cynthia M Westerhout; Yuling Fu; Michael S Lauer; Stefan James; Paul W Armstrong; Eyad Al-Hattab; Robert M Califf; Maarten L Simoons; Lars Wallentin; Eric Boersma
Journal:  J Am Coll Cardiol       Date:  2006-09-05       Impact factor: 24.094

5.  Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.

Authors:  H Toss; B Lindahl; A Siegbahn; L Wallentin
Journal:  Circulation       Date:  1997-12-16       Impact factor: 29.690

6.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  N Engl J Med       Date:  2008-11-09       Impact factor: 91.245

7.  C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction.

Authors:  D A Morrow; N Rifai; E M Antman; D L Weiner; C H McCabe; C P Cannon; E Braunwald
Journal:  J Am Coll Cardiol       Date:  1998-06       Impact factor: 24.094

8.  Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome.

Authors:  Teruo Inoue; Toru Kato; Kan Takayanagi; Toshihiko Uchida; Isao Yaguchi; Hirotoshi Kamishirado; Shigenori Morooka; Nobuo Yoshimoto
Journal:  Am J Cardiol       Date:  2003-12-15       Impact factor: 2.778

9.  Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction.

Authors:  D Kelly; S Khan; G Cockerill; L L Ng; M Thompson; N J Samani; I B Squire
Journal:  Eur J Heart Fail       Date:  2008-01-30       Impact factor: 15.534

10.  Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association.

Authors:  Mark A Hlatky; Philip Greenland; Donna K Arnett; Christie M Ballantyne; Michael H Criqui; Mitchell S V Elkind; Alan S Go; Frank E Harrell; Yuling Hong; Barbara V Howard; Virginia J Howard; Priscilla Y Hsue; Christopher M Kramer; Joseph P McConnell; Sharon-Lise T Normand; Christopher J O'Donnell; Sidney C Smith; Peter W F Wilson
Journal:  Circulation       Date:  2009-04-13       Impact factor: 29.690

View more
  9 in total

Review 1.  A Guide for a Cardiovascular Genomics Biorepository: the CATHGEN Experience.

Authors:  William E Kraus; Christopher B Granger; Michael H Sketch; Mark P Donahue; Geoffrey S Ginsburg; Elizabeth R Hauser; Carol Haynes; L Kristin Newby; Melissa Hurdle; Z Elaine Dowdy; Svati H Shah
Journal:  J Cardiovasc Transl Res       Date:  2015-08-14       Impact factor: 4.132

2.  Serum IGF-binding protein 2 (IGFBP-2) concentrations change early after gastric bypass bariatric surgery revealing a possible marker of leptin sensitivity in obese subjects.

Authors:  Giovanni Ceccarini; Caterina Pelosini; Federica Ferrari; Silvia Magno; Jacopo Vitti; Guido Salvetti; Carlo Moretto; Antonio Marioni; Piero Buccianti; Paolo Piaggi; Margherita Maffei; Ferruccio Santini
Journal:  Endocrine       Date:  2019-04-03       Impact factor: 3.633

Review 3.  The Translation and Commercialisation of Biomarkers for Cardiovascular Disease-A Review.

Authors:  Soloman Saleh; Jacob George; Katharine A Kott; Peter J Meikle; Gemma A Figtree
Journal:  Front Cardiovasc Med       Date:  2022-06-02

4.  Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease.

Authors:  Debby Ngo; Sumita Sinha; Dongxiao Shen; Eric W Kuhn; Michelle J Keyes; Xu Shi; Mark D Benson; John F O'Sullivan; Hasmik Keshishian; Laurie A Farrell; Michael A Fifer; Ramachandran S Vasan; Marc S Sabatine; Martin G Larson; Steven A Carr; Thomas J Wang; Robert E Gerszten
Journal:  Circulation       Date:  2016-07-26       Impact factor: 29.690

Review 5.  Multiplex biomarker approach to cardiovascular diseases.

Authors:  Michaela Adamcova; Fedor Šimko
Journal:  Acta Pharmacol Sin       Date:  2018-04-12       Impact factor: 6.150

6.  Composable Microfluidic Plates (cPlate): A Simple and Scalable Fluid Manipulation System for Multiplexed Enzyme-Linked Immunosorbent Assay (ELISA).

Authors:  Ziyi He; Justin Huffman; Kathrine Curtin; Krista L Garner; Elizabeth C Bowdridge; Xiaojun Li; Timothy R Nurkiewicz; Peng Li
Journal:  Anal Chem       Date:  2020-12-16       Impact factor: 6.986

7.  Predicting the outcomes for out-of-hospital cardiac arrest patients using multiple biomarkers and suspension microarray assays.

Authors:  Chien-Hua Huang; Min-Shan Tsai; Kuo-Liong Chien; Wei-Tien Chang; Tzung-Dau Wang; Shyr-Chyr Chen; Matthew Huei-Ming Ma; Hsin-Yun Hsu; Wen-Jone Chen
Journal:  Sci Rep       Date:  2016-06-03       Impact factor: 4.379

Review 8.  Current IGFBP-Related Biomarker Research in Cardiovascular Disease-We Need More Structural and Functional Information in Clinical Studies.

Authors:  Andreas Hoeflich; Robert David; Rikke Hjortebjerg
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-16       Impact factor: 5.555

9.  Expression of Nik-related kinase in smooth muscle cells attenuates vascular inflammation and intimal hyperplasia.

Authors:  Yi-Jhu Lu; Yee-Jee Jan; Bor-Sheng Ko; Shu-Man Liang; Lujen Chen; Chih-Cheng Wu; Chih-Hui Chin; Cheng-Chin Kuo; Shaw-Fang Yet; Jun-Yang Liou
Journal:  Aging (Albany NY)       Date:  2020-04-24       Impact factor: 5.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.